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Abstract: Tetraspanins are exposed at the surface of cellular membranes, which allows for the fixation
of cognate antibodies. Developing specific antibodies in conjunction with genetic data would largely
contribute to deciphering their biological behavior. In this short review, we summarize the main
functions of Tspan8/Co-029 and its role in the biology of tumor cells. Based on data collected from
recently reported studies, the possibilities of using antibodies to target Tspan8 in immunotherapy or
radioimmunotherapy approaches are also discussed.
Keywords: tetraspanins; cancer; Tspan8; immunotherapy; radioimmunotherapy
1. Introduction
Tspan8 belongs to the tetraspanin molecular family of surface glycoproteins containing
33 members in humans, which are now referred to as Tspan1–33 (Figure 1). Tetraspanins are small
membrane proteins (200–350 amino acids), which interact laterally with multiple partner proteins
and with each other to form the so-called TEMs (tetraspanin-enriched microdomains). To qualify
for membership in the tetraspanin family, a protein must have four transmembrane domains and
several conserved amino acids, including an absolutely conserved CCG motif and two other cysteine
residues that contribute to two crucial disulfide bonds within the second extracellular loop (EC2)
(Figure 2). One or two additional disulfide bonds may also be found in EC2. The biological
importance of tetraspanins is supported by functional consequences of genetic modifications that
occur either spontaneously in humans or experimentally in mice. For instance, gene inactivation
may affect fertility (CD9, CD81), and visual (RDS), kidney (CD151) or immunological functions
(CD81, CD37) [1–4]. Since tetraspanins are not adhesion or signaling molecules, receptors or
enzymes, the properties of these molecules are highly dependent on their ability to form TEMs
with a hierarchical organization. Indeed, each tetraspanin has specific partners, including integrins,
ADAM metalloproteases, growth factor receptors and histocompatibility antigens, that they are directly
associated with through protein–protein interactions and form primary complexes with [5,6]. Coupled
together, the latter can form second-order complexes through tetraspanin–tetraspanin interactions
that may involve cholesterol and palmitoylation. In some cases, the function of these associated
molecules has not yet been elucidated for the CD9P-1 and EWI2 (official protein names of PTGFRN
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and IGSF8) [7,8]. Some molecular experiments showed that tetraspanins may interfere with the
properties (affinity of the integrin α6β1 for laminin-1 is modulated by the tetraspanin CD151) [9],
the trafficking (CD81 controls the expression of CD19 at the B-lymphoid cell surface) [10] or membrane
compartmentalization of associated molecules (such as ADAM10 by TspanC8) [11]. Detailed proteomic
analysis of membrane molecules that are able to associate with CD9 and Tspan8 has been reported
recently in colon carcinoma cell lines. Among other membrane proteins, E-cadherin and EGFR are
associated with TM4 complexes. More specifically, the presence of Tspan8 in the membrane drives
EGFR to tetraspanin complexes, which results in changes in motility behavior (see next paragraph) [12].
Figure 1. Homology tree between human tetraspanins. Protein sequences have been aligned to generate
this distance tree. Bolded names correspond to commonly used ones. The number of cysteines in the
extracellular loop EC2 is given when they are different from six cysteines.
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Figure 2. Schematic representation of Tspan8 in membrane. The transmembrane (TM) domains inserted
in the phospholipid bilayer are palmitoylated with a cholesterol molecule in between these domains
(by analogy with CD81 structure [13]). Among the two extracellular (EC) regions, the larger region
contains six cysteines involved in disulfide bonds. EC1 and EC2 = extracellular domains 1 and 2;
Ch = cholesterol; and PL = phospholipid.
Some tetraspanins are widely expressed (for example, CD81 and CD151) while others are
more restricted (for example, CD37 and CD53 on lymphoid cells or RDS in retina). Several clinical
observations and experimental data have correlated the expression of some tetraspanins with tumor
metastatic potential. CD82 or CD9 expression is generally associated with favorable prognosis in
different cancers [3]. On the contrary, CD151 and Tspan8 expression in tumor cells has been frequently
associated with increased migration, proliferation and angiogenesis induction (Table 1). Mechanisms
that could potentially explain the role of tetraspanins in tumors have been investigated experimentally
using cellular models of overexpression in addition to knockdown or knockout animal models
(reviewed in references [3,4,14–16]). The modulation of cellular properties, such as proliferation,
cell migration and apoptosis, has been previously reported. Among other mechanisms, the knockout
of CD37 leads to the occurrence of lymphomas that appear to be linked to the constitutive activation of
the IL6 signaling pathway [17]. At a tissue level, an effect of Tspan8 on angiogenesis could be partially
mediated by exosomes. More generally, the role of tetraspanins in tumor cell communication with
their microenvironment through an effect on exosomal biogenesis is considered to be an important
function of these molecules [18]. The changes in cell properties induced by the (over)expression
of Tspan8 have been investigated in preclinical models. For example, the Isreco1 cell line derived
from primary colorectal cancer (CRC) that does not express Tspan8 was compared with Is1-Co029,
which was obtained by transduction to express Tspan8 at the same level as the two cell lines derived
from metastases of the same patient. There was no difference in the motility of single cells plated on
collagen, but RNAi targeting various surface molecules, such as E-cadherin, p120-catenin or EGFR,
increased the motility of Is1-Co029, whereas no effect was observed on Isreco1 [12,19]. A possible
link between Tspan8, E-cadherin and motility could be the signaling molecule p120-catenin, which is
retained at the cell membrane through its affinity for E-cadherin. Furthermore, it has been reported to
regulate Rho and Rac functions in cell adhesion and motility (reviewed in reference [19]). However,
models using long-term established tumor cell lines in 2D settings could be misleading and it would
be important to conduct experiments on cells derived from fresh tumors and cultured in 3D conditions
as organoids that would better reflect the in-vivo conditions.
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Table 1. Summary of studies dealing with biological consequences of Tspan8 targeting using specific antibodies.
Preclinical and clinical models Effect of Tspan8 Expression and Modulation by Antibody or Tspan8-LEL Targeting onMigration/Invasion/Metastasis, Proliferation/Tumor Growth, Angiogenesis References
Rat pancreatic adenocarcinoma cells (AS-Tspan8 vs. AS)
In vitro: similar proliferation of two AS cell lines
Inhibition by anti-rat Tspan8 mAb D6.1 of AS-Tspan8
In vivo: increased metastasis formation of AS-Tspan8 (i.v., s.c. or i.f.p. injection)
[20]
Rat pancreatic adenocarcinoma cells (AS-Tspan8 vs. AS) In vitro: increased endothelial cell branching blocked by mAb D6.1In vivo: peritoneal carcinosis—increased vessel density (intravital microscopy) abolished by mAb D6 [21]
Highly metastatic rat pancreatic adenocarcinoma
BSp73ASML (+/−Tspan8 knockdown)
In vitro: transwell migration and wound healing: reduced in BSp73ASML-Tspan8kd and by mAb D6.1
in BSp73AMSL
No effect of D6.1 on BSp73ASML single-cell motility
In vivo: delayed metastasis and prolonged survival in BSp73ASML-Tspan8kd
[22]
Human colorectal cancer
cell lines: Isreco1 and Is-Co029(Tspan8)
HT-29, SW480 and SW480-Tspan8
Patients: IHC: Tspan8 high expression correlated with worse prognosis
In vitro: single cell-motility on collagen I increased by Ecad, p120ctn and EGFR RNAi when Tspan8 is
expressed. This effect is reversed by anti-mouse Tspan8 mAb Ts29.1. No effect of mAb Ts29.1 or Ts29.2
on proliferation
In vivo (nude mice): tumor growth reduced by i.p. injection of mAb Ts29.2
No effect on angiogenesis (IHC–CD34 labeling)
Tumor growth inhibition by i.v. injection of [177Lu]DOTA-Ts29.2
[12,19,23,24]
Human ovarian cell line—effect of Tspan8 RNAi,
Tspan8-LEL-Fc, Tspan8-LEL IgG (human Ab selected
by phage display)
In vitro: invasion in Matrigel-coated Transwell is inhibited by the 3 reagents
In vivo: partial metastasis inhibition (SK-OV3-Luc) by i.v. injection of Tspan8-LEL IgG [25]
i.v.: intravenous, i.p.: intraperitoneal, i.f.p: intrafootpad and s.c.: subcutaneous.
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Experimental results and clinical trials using monoclonal antibodies (mAbs) suggest that some
tetraspanins may be targeted in hematological malignancies and carcinomas [26]. In a similar
way, Tspan8 appears to be an interesting candidate for the development of therapeutic antibodies,
and different methods are discussed in the last part of this review.
2. Mechanisms and Requirements for the Use of Therapeutic Anti-Tetraspanin Antibodies
2.1. Molecular Mechanisms
Since antibodies are large proteins, their ability to reach their target may be limited by
their diffusion inside different tissues and their components due to certain barriers, such as the
hemato-encephalic barrier. However, since the permeability of tumor vessels is usually abnormal,
diffusion appears to be increased in such tumor tissues [27,28]. Once located close to their biological
target, the antibodies can enact different mechanisms of action.
2.1.1. Blocking Antibodies
According to current knowledge, the action of tetraspanins relies on their ability to regulate the
function of their partner molecules. Even if the detailed molecular basis remains mostly unknown,
the binding of mAbs on Tspan8 may result in the inhibition of cell migration, invasion, proliferation
and angiogenesis in organized tissues (Table 1).
2.1.2. Cytotoxic Antibodies
Unconjugated antibodies mediate ADCC (antibody-dependent cell cytotoxicity) via the activation
of accessory cytotoxic cells for killing target cells. Upon fixation on the cell surface, they recruit
macrophages or NK cells through their Fc fragment, which can further destroy the target cell.
The subclass and glycosylation of the Fc region are important parameters that determine the efficacy
of ADCC. Furthermore, the ability of antibodies to mediate ADCC may be optimized through genetic
modification of their Fc region.
On the contrary, radionuclide- or drug-conjugated antibodies have directly toxic effects in vivo.
Depending on the radionuclide used (nature of emissions, energy and so on),
radionuclide-conjugated antibodies can efficiently treat the target cells and the neighboring
cells, which can be of high value in the case of heterogeneous cell expression of the target molecule.
In addition, radionuclide-conjugated antibodies can also allow for a combination of imaging and
radiotoxicity. This will be detailed in the radionuclide-conjugated Tspan8 antibodies section.
When antibodies are conjugated with cytotoxic drugs, an internalization of the antigen/antibody
complex is often necessary to allow drug delivery [29]. However, if the targeted protein is widely
distributed, the use of these two main categories of antibody–drug conjugates may have deleterious
effects on normal tissues. As a consequence, the careful evaluation of the pattern of expression of the
target is a critical prerequisite for the development of a therapeutic antibody. However, recent progress
in antibody-conjugated drugs has allowed one to target more specific released molecules in tumors.
For instance, cleavage in acidic zones that occur in the highly proliferative zone or proteolytic cleavage
by tumor enzymes, such as MMPs, increase specificity. Another stage was added with a pro-body
approach, which consists of modifying the antibody with a small peptide that needs to be cleaved by a
specific protease for antigen recognition [30].
2.2. Pattern of Expression
An ideal antigenic target should be expressed at a high intensity on the surface of tumor cells,
especially tumor stem cells and not on normal cells. None of the molecules that are currently targeted
by mAbs are able to fulfil these criteria and not surprisingly, tetraspanins do not escape this rule.
As mentioned above, the tissue distribution of tetraspanins is highly variable. A very restricted
distribution of some tetraspanins has already been observed for peripherin/RDS found in the
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photoreceptors, UPk1a found on the urinary bladder epithelium or CD37 expressed mainly on B
lymphoid cells. In contrast, other tetraspanins, such as CD9, CD63, CD81 or CD151, have a very
large distribution and may be difficult to target in vivo. Tspan8 is expressed in a limited number of
tissues and is mainly found on epithelial cells of the digestive tract. However, it is also located on
the epithelial cells of the kidney, prostate and trachea [23]. The second aspect relates to the intensity
ratio of Tspan8 in tumor compared to normal tissues, which is another crucial issue that needs to be
addressed in order to avoid side effects. Increased Tspan8 expression in tumor tissues (colorectal and
ovarian cancer, melanoma, hepatocellular and pancreatic carcinoma) is generally related to worse
prognosis [19,25,31–33]. Therefore, Tspan8 appears to be an interesting target candidate for cancer
treatment with mAbs.
2.3. Dodging Immune Neutralization
This important point has been widely studied and previously reviewed. Thus, this will not be
detailed in this article. This is mainly realized through the humanization of the molecule but other
methods have been previously reported [34].
3. Therapeutic Antibodies Directed toward the Tetraspanins CD9, CD151 and CD37 in Cancer
There are a few proofs of principle that have shown that targeting tetraspanins with antibodies
might inhibit tumor growth or even induce partial or complete remission [35].
The effects of the anti-CD9 mAb ALB6 (IgG1) injected intravenously were investigated in a model
of human gastric cancer (MKN-28) implanted subcutaneously in nude mice. A reduction of 60–70%
in the size of the tumor in the treated group was observed compared to the control IgG-treated mice.
At the same time, a significant reduction in cell proliferation and angiogenesis and an increase in
apoptotic signals were observed [36]. Since this mAb is directed towards human CD9, damages
to normal tissues were not evaluated. As CD9 is strongly expressed on many cellular types and
particularly on platelets in humans, the use of this anti-CD9 antibody could lead to a loss of treatment
efficiency and may trigger platelet activation or lysis depending on the nature of the Fc fragment [37].
However, Fc-mediated side effects could be avoided by genetic modifications of the antibody.
There have only been a few studies targeting tetraspanins in humans for therapeutic purposes.
A cocktail of antibodies Ba1/2/3 directed respectively toward CD9, CD24 and CD10 to deplete the bone
marrow of acute lymphoblastic leukemia patients for autologous bone marrow transplantation was
investigated. Even if the specific role of each individual antibody was difficult to evaluate, an absence
of toxicity against hematological stem cells was observed in these antibodies [38].
Due to its restricted specificity for differentiated cells of the B-cell lineage, CD37 was considered to
be a potential target for the treatment for B-cell lymphoma using an anti-CD37 antibody radiolabeled
with iodine-131 (β−; T1/2 = 8.02 d; 606 keV). Very encouraging results were obtained in comparison
with an anti-CD20 antibody labelled with the same radionuclide [39]. However, since the use of
unconjugated humanized anti-CD20 mAbs for B-cell lymphoma has been a very straightforward
method for the improvement of treatment protocols, the use of anti-CD37 mAbs for the treatment of
lymphoma and chronic lymphocytic leukemia was abandoned and only recently reintroduced. Several
forms of therapeutic anti-CD37 antibodies, whether they are human or humanized, used in combination
or alone (unconjugated antibodies (Bi 836826 and otlertuzumab) and drug conjugates (monomethyl
auristatin E: AGS67E, maytansine: IMGN529)), or radiolabeled antibodies (177Lu: belatutin) [40],
have been developed and are currently undergoing clinical tests. Promising results have been obtained
in the resistant forms of NHL (Non-Hodgkin Lymphomas) and CLL (Chronic Lymphocytic Leukemias).
Anti-CD151 antibodies inhibited metastasis spread and primary tumor growth in human tumor
mouse models [41,42]. Despite their variable ability to disrupt the complex between CD151 and α3β1
integrin, different anti-CD151 antibodies were reported to prevent metastasis formation in clinical
models [35].
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4. Treatment with Unconjugated Anti-Tspan8 Antibodies
Unconjugated mAbs may act through two different mechanisms, which are namely the mediation
of ADCC or interference with molecular functions that are required for malignant cells to express
their tumorigenicity. The functional activity of the anti-Tspan8 mAbs can be assessed to some extent
in vitro but the link between tumor growth inhibition and either ADCC or functional inhibition could
be difficult to determine in vivo.
Several studies were performed by Zöller’s group with the rat pancreatic adenocarcinoma cells
(AS-Tspan8 compared to AS). The anti-rat Tspan8 mAb D6.1 was found to inhibit cell proliferation
in vitro [20]. Furthermore, in rat mesentery fragments cultured with tumor cells or their exosomes,
increased endothelial cell branching linked to Tspan8 expression was blocked by mAb D6.1 [21].
These studies suggest that Tspan8 overexpression in rats promotes angiogenic activity and supports
tumor growth while anti-rat Tspan8 mAbs can efficiently inhibit this process. In addition, increased
vessel density observed by intravital microscopy was abolished after treatment with D6.1 in an in-vivo
model of peritoneal carcinosis [21].
Anti-human Tspan8 mAbs (Ts29.1: IgG1 and Ts29.2: IgG2b) were produced by Boucheix’s team.
These antibodies had no effect on cell proliferation, migration or apoptosis for colorectal cancer
(CRC) cell lines Isreco-1/Is1-Co029, SW480 (presenting spontaneously weak Tspan8 expression) and
SW480-Co029 (overexpressing Tspan8 after gene transduction) in vitro. However, the 2D motility of
Is1-Co029 was increased by RNAi targeting E-cadherin and p120-catenin while it only decreased after
specific co-treatment with anti-Tspan8 mAbs [12,19]. EGFR blocking (mAb cetuximab or AG1478,
a chemical EGFR inhibitor) in Is1-Co029 cells also induced an increase in cell motility, which was further
blocked by treatment with anti-Tspan8 mAbs [12]. The observations in relation to EGFR inhibition
were unexpected since Isreco-1 cell lines have a KRAS mutation, which should be associated with an
inhibition of the EGFR function. Thus, this suggested that EGFR signaling may still be influenced
when Tspan8 is expressed.
In a mouse model of CRC (SW480 vs. SW480-Co029), the growth of SW480-Co029 tumors was
inhibited by up to 70% when treated in the early stages with the IgG2b anti-human Tspan8 mAbTs29.2
in vivo (initially 2 mg intraperitoneally, followed by 1 mg twice a week for 4 weeks). The same
results were also observed in another CRC mouse model, which expressed spontaneously high levels
of Tspan8 (HT29). The inhibition of the cell proliferation in vivo was demonstrated by a reduction
of the mitotic index in HT29 tumor cells in Ts29.2-treated mice. These in-vivo data underlined the
crucial role of Tspan8 in tumor growth and the therapeutic potential of anti-Tspan8 mAbs as a CRC
treatment. The discrepancy between the in-vitro and in-vivo data on cell proliferation suggested that
the binding of Ts29.2 to tumor cells may modify their response to signaling from the microenvironment.
No significant differences between the treated and control mice were found when assessing the
inflammatory infiltrate, angiogenesis (CD34) and apoptotic signal (Casp3). These findings did not
support the hypothesis of ADCC.
In another approach targeting Tspan8, Park et al. [25] used phage display technology to produce
a fully human mAb directed against Tspan8 LEL (large extra loop = EC2). For an in-vivo experiment,
the mice that were intraperitoneally injected with SK-OV3-luc human ovarian cell line intravenously
received either IgG or Tspan8–LEL IgG (10 mg/kg) twice a week until day 42 post inoculation. In the
control IgG-treated group, a detectable luminescence signal in removed organs (ovary, pancreas, colon,
heart, liver, spleen and kidney) was observed in 24 of 31 control mice whereas the incidence fell to
50% (15 of 30 mice) in the Tspan8–LEL IgG-treated group. This reduction of 35% was considered to be
significant and the mice did not show any signs of severe toxicity.
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5. Treatment with Radionuclide-Conjugated Anti-Tspan8 Antibodies
5.1. Radiolabeling of Antibodies
For radiotherapeutic purposes, antibodies are usually modified with grafted chelating moieties
to allow radiolabeling with β−-emitter radionuclides like yttrium-90 (β−; T1/2 = 2.67 d; 2280 keV)
or lutetium-177 (β−; T1/2 = 6.65 d; 498 keV) [43]. Advantageously, lutetium-177 can be used for both
imaging and therapeutic purposes as β− and γ radiations are generated during its decay. To date,
the only radiolabeled mAb authorized for human treatment is the anti-CD20 [90Y]ibritumomab tiuxetan
(Zevalin®), which is administered as a second-line treatment to patients with non-Hodgkin lymphomas
(NHLs) that are resistant to chemotherapy [44]. Although they were created several decades ago,
radioimmunotherapy (RIT)sing β−-emitter—conjugated mAbs remains underused due to inherent
issues concerning hematotoxicity, which is induced by the long biological half-life of mAbs in blood,
and the low penetration of antibodies in solid tumors [43,45]. Thus, different strategies have been
proposed to enhance RIT efficiency, including the use of α-particle emitters, pretargeting protocols and
reduction/modification of the antibody size (nanobodies, affibodies and so on).
The use of α-particle emitters is of great interest for delivering high linear energy transfer
(LET) in very small volumes (cell diameters of 50–100 µm) without affecting neighboring tissues.
Among the increasing number of clinical studies using mAbs/peptides/ligands/radionuclides
delivering α-particles [46], two mAbs radiolabeled with bismuth-213 (α; T1/2 = 45.6 min; 5869 keV)
(213Bi-cDTPA-9.2.27 targeting MSCP in melanoma and 213Bi-Hum195 mAb targeting CD33 in acute
myeloid leukemia) have had positive results in terms of prognosis [47,48]. Moreover, challenging
approaches using DOTA-mAbs radiolabeled with actinium-225 (α; T1/2 = 10.0 d; 5580–5830 keV)
are currently under investigation as this radionuclide decay generates francium-221 (α; T1/2 = 4.79 min,
6300 keV), which has an interesting secondary radiotoxic effect [49]. This strategy should be applied
for internalizing antibodies to concentrate α-particles in tumor cells.
To decrease hematotoxicity, different pretargeting strategies were developed to dissociate the mAb
antibody and radionuclide injections [50]. One of the most interesting approaches involves the use of
bio-orthogonal chemistry. In such strategies, the mAb and the delayed injected radioactive molecule
are grafted with chemical entities that are highly reactive to each other but inert to chemical functions
usually found on in-vivo molecules, such as proteins. This fast and specific reaction can advantageously
take place in aqueous media, which is compatible with in-vivo applications. Another way of reducing
side effects of RIT is to inject the radioactive molecule in a specific organ to avoid systemic irradiation.
For example, this might involve intrahepatic metastases using arterial infusions [51].
Finally, different small protein forms (affibodies, nanobodies and so on) ranging from a few to
30 kDa with a shorter biological half-life in the blood circulation have been tested in preclinical RIT
protocols [52] but mostly in nonradioactive applications. In clinical trials, one affibody is currently being
investigated in Her2 breast cancer imaging [53].
5.2. Targeting Tspan8 with Radiolabeled Antibodies
Our team investigated the biodistribution of two monoclonal antibodies targeting human Tspan8,
which were namely Ts29.1 and Ts29.2. These were grafted with DOTA and radiolabeled with indium-111
(γ; T1/2 = 2.80 d; 171 keV; 245 keV). The measurement of the immunoreactive fraction revealed that
the addition of DOTA-chelating moieties and radiolabeling did not modify the affinity of Ts29.2 for its
target. The uptake of [111In]DOTA-Ts29.2 in HT29 tumors was higher than that of [111In]DOTA-Ts29.1
(Figure 3A,B). After this, further experiments were conducted on different models of xenografts [23].
Biodistribution studies on mice with both SW480-Co29/SW480 tumors demonstrated high specificity
of [111In]DOTA-Ts29.2 for Tspan8-expressing tumors. The same results were obtained using the Isreco-1
and Is1-Co029 models (Figure 4A,B). Further RIT experiments using this antibody were supported by the
promising biodistribution and dosimetry results collected. During therapeutic studies, we observed that
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[177Lu]DOTA-Ts29.2 induced a significant reduction in HT29 xenograft growth, with molecular events
sustaining the effects of the radiation in this model.
Figure 3. In-vivo selection of [111In]DOTA-Ts29 antibodies for imaging and therapy in mice with HT29
colon carcinoma xenografts. Nude NMRI mice with HT-29 tumors were injected (i.v.) with 3.7 MBq of
[111In]DOTA-Ts29.1 (upper images) or [111In]DOTA-Ts29.2 (lower images), which were imaged with a
planar γ-camera at 4 h, 24 h, 72 h, 120 h and 168 h post injection (A). Biodistribution was performed
after euthanasia and expressed as the percentage of activity injected per gram of tissue (%AI/g)
of [111In]DOTA-Ts29.1 (orange) or [111In]DOTA-Ts29.2 (purple) (B). Radioactivity was measured using
a γ-counter. Results are presented as the average percentage of injected dose/gram of tissue of three
animals for each time point. The error bars represent the standard deviation. Biodistribution difference
between the two mAbs: * p < 0.05 Fisher test.
Figure 4. In-vivo specificity of [111In]DOTA-Ts29.2 for Tspan8-expressing tumors. Nude NMRI
mice with Isreco-1 (left shoulder) and Is1-Co29 (right shoulder) were injected (i.v.) with 3.7 MBq of
[111In]DOTA-Ts29.2 and imaged with a planar γ-camera at 4 h, 24 h, 72 h and 120 h post injection (A).
Ex-vivo biodistribution study (%AI/g) of [111In]DOTA-Ts29.2 (B) was determined on the same mice with
the same protocol as Figure 3B. Biodistribution difference between the two tumors: * p < 0.05. Fisher test.
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To initiate the pretargeting strategies, Ts29.2 was also modified by the addition of a
transcyclooctene (TCO) to the lysine residues, which was evaluated in studies conducted in vitro
and in vivo using a fluorescent tetrazine. We evaluated the best link size between TCO and TS29.2 and
observed a higher fluorescent signal with Ts29.2-TCO without a PEG spacer, which can be explained
by a higher isomerization rate of TCO to the inactive CCO form [54]. As tetrazin can be conjugated
to a DOTA group, RIT with β−-emitters or α-particles will be considered. A recent preclinical study
using such an approach had significant effects on mice xenografted with ovarian tumors and treated
with an anti-CEA-TCO for 72 h before radionuclide injection [55].
5.3. Pros and Cons of RIT for Human Cancers: Focus on Targeting Tspan8
Stoichiometrically compared to its corresponding nonradiolabeled antibodies,
[177Lu]DOTA-Ts29.2 induced a greater slowing down of tumor growth. The main features in
pretargeted radioimmunotherapy PRIT experiments were the reduction of proliferation and
increase in apoptosis. As mentioned above, the treatment with nonradioactive antibodies (using
100-times more antibodies than in the [177Lu]DOTA Ts29.2 experiments) also resulted in a slowing
down of tumor growth with neither induction of apoptosis nor decrease in angiogenesis. In fact,
the nonradioactive antibody should alter the interactions between tumor cells harboring Tspan8
and the microenvironment while its radiolabeled counterpart irradiates all surrounding cells after
it attaches to its target antigen. This property should be interesting as it will decrease the number
of so-called cancerous stem cells (CSCs) because Tspan8 has been identified on the surface of CSCs
in pancreatic tumors [56]. RIT has been proven to be effective in stopping CSCs in melanomas
using preclinical models, which utilized an IgM directed toward melanin and radiolabeled with
rhenium-188 [57]. Conversely, Tspan8 is exposed on the surface of circulating exosomes [22], leading
to potential blood radiotoxicity in RIT experiments. Apart from this potential disadvantage, one can
imagine that targeting circulating exosomes will be of interest as these vesicles are implicated in
metastatic spread [58]. As mentioned above, the hematotoxicity might be prevented by pretargeting
strategies, which will be further reinforced by the use of blood clearing agents such as nonradiolabeled
ligands conjugated to albumin [59]. As an example, this might allow their metabolism in the liver.
Tspan8 expression is restricted and this protein has been described as a significant contributor
and potential therapeutic target in several cancer types. Even if secondary effects and immune system
involvement cannot be evaluated on tumor-grafted mouse models used for these studies, targeting
Tspan8 with radiolabeled antibodies seems to be an effective antitumoral therapy.
6. Conclusions
Tetraspanins may have a broad range of actions in cancers due to their intrinsic membrane
localization (cell membrane or exosomes) and high numbers of their interacting molecules [3,26].
The aim of this article was to review recent preclinical attempts at targeting tetraspanins in cancer with
a focus on Tspan8. Unconjugated antibodies and radionuclide-conjugated antibodies conceptually
represent two different approaches for killing cancer cells through the expression of a surface molecule.
Antibodies may have complex effects as they combine cell-mediated cytotoxicity and functional
deleterious effects, such as apoptosis induction, or invasive growth and angiogenesis inhibition.
This can occur directly or through microenvironment factors. For tetraspanins, it is still unknown how
the targeting can alter the function of tumor cells in vivo, but their association with adhesion molecules,
growth factor receptors or enzymes inside membrane molecular complexes leads to disturbance of the
structure/composition of these complexes, which may result in modulation of migration and abnormal
signaling into the cell and finally, inhibition of invasion/metastasis or even apoptosis. A better view
and understanding of the behavior of tumor cells in real life would require improved models (such as
3D in-vitro setups with microenvironment reconstitution or syngeneic models in vivo). Although the
mechanism of action of radionuclide antibodies is simple and straightforward, their manufacturing
requires careful technical management and radioprotection protocols at all stages of their manipulation.
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However, these offer interesting potential and should be pursued in the future. Innovative techniques
have also been developed to reduce harmful effects that are linked to the antibodies binding to normal
healthy tissue.
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